abstract |
The present disclosure provides methods and compositions for treating or preventing dengue virus infection in a vertebrate animal. In particular, the present disclosure discloses human neutralizing monoclonal antibodies against dengue virus isolated from EBV immortalized B cells derived from a patient recovering from a dengue infection. The present disclosure provides a method of administering such antibodies to vertebrate animals in an amount effective to reduce, eliminate, or prevent recurrence from infection. |